Toggle light / dark theme

Abstract: The antibody Teplizumab can delay type 1 diabetes, but therapeutic responses are heterogeneous

Here, Conny Gysemans & team find variable patient responses align with specific immune gene signatures, offering a tool to predict treatment success or resistance.


Address correspondence to: Conny Gysemans, Leuven Diabetes Lab, Clinical and Experimental Endocrinology (CEE), CHROMETA, KU Leuven, Leuven, Belgium. Phone: 32.16.377454; Email: [email protected].

Leave a Comment

Lifeboat Foundation respects your privacy! Your email address will not be published.

/* */